M. France

发表

Indications for cholesterol-lowering medication: comparison of risk-assessment methods

D. Bhatnagar, D Bhatnagar, P. Durrington, 1999, The Lancet.

Impaired glucose tolerance and insulin insensitivity in primary hyperparathyroidism

A. Boulton, S. Kumar, J. Hosker, 1994, Clinical endocrinology.

The withdrawal of the thyromimetic eprotirome

M. France, 2014 .

Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS)

G. Hitman, D. Demicco, D. Betteridge, 2009, Diabetologia.

Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS).

G. Hitman, D. Demicco, D. Betteridge, 2009, Clinical chemistry.

An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia

P. Durrington, D. Bhatnagar, M. Mackness, 2001, Heart.

Quantitative evaluation of statin effectiveness versus intolerance and strategies for management of intolerance.

H. Soran, P. Durrington, Zohaib Iqbal, 2020, Atherosclerosis.

Survival among hospital in-patients with troponin T elevation below levels defining myocardial infarction.

R. Heller, D. Taylor, G. Lyratzopoulos, 2005, QJM : monthly journal of the Association of Physicians.

Treatment of homozygous familial hypercholesterolemia

H. Soran, M. France, S. Kwok, 2014 .

Screening for cardiovascular risk factors in patients admitted for acute coronary syndrome

R. Pearson, M. Banerjee, S. Hama, 2014, International journal of clinical practice.

Diet Treatment of Newly Presenting Type 2 Diabetes Improves Insulin Secretory Capacity, but Has No Effect on Insulin Sensitivity

A. Boulton, A. Boulton, S. Kumar, 1993, Diabetic medicine : a journal of the British Diabetic Association.

Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients

R. Donn, A. Stevens, S. Hama, 2015, Journal of the American Heart Association.

Knowledge gaps in the management of familial hypercholesterolaemia. A UK based survey.

H. Soran, K. Ray, N. Capps, 2016, Atherosclerosis.

Apolipoprotein B100 is a better treatment target than calculated LDL and non-HDL cholesterol in statin-treated patients

H. Soran, P. Durrington, V. Charlton-Menys, 2011, Annals of clinical biochemistry.

Lp(a): When and how to measure it

S. Marcovina, R. Neely, M. France, 2020, Annals of clinical biochemistry.

Liver Fat Measured by MR Spectroscopy: Estimate of Imprecision and Relationship with Serum Glycerol, Caeruloplasmin and Non-Esterified Fatty Acids

Yifen Liu, H. Soran, P. Durrington, 2016, International journal of molecular sciences.

HEART UK consensus statement on Lipoprotein(a): A call to action.

C. Shoulders, N. Qureshi, G. Ferns, 2019, Atherosclerosis.

HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom.

C. Shoulders, U. Ramaswami, G. Ferns, 2016, Atherosclerosis.

High-density lipoprotein cholesterol raising: does it matter?

Yifen Liu, B. Ammori, H. Soran, 2013, Current opinion in cardiology.

Rapid exclusion of acute myocardial infarction in patients with undetectable troponin using a high-sensitivity assay.

A. Jaffe, R. Body, S. Carley, 2011, Journal of the American College of Cardiology.

Extended-release niacin with laropiprant: a review on efficacy, clinical effectiveness and safety

S. Hama, B. Ammori, N. Younis, 2012, Expert opinion on pharmacotherapy.

A comparison of the effects of low- and high-dose atorvastatin on lipoprotein metabolism and inflammatory cytokines in type 2 diabetes: Results from the Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA) randomized trial.

M. Rutter, M. Gittins, Yifen Liu, 2017, Journal of clinical lipidology.

Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double‐blind placebo‐controlled trial of high‐ vs. low‐dose atorvastatin 1

M. Gittins, P. Durrington, V. Charlton-Menys, 2011, Diabetic medicine : a journal of the British Diabetic Association.

Managing hyperlipidaemia in patients with COVID-19 and during its pandemic: An expert panel position statement from HEART UK

N. Qureshi, G. Ferns, J. Halcox, 2020, Atherosclerosis.

Effect of Roux-en-Y Bariatric Surgery on Lipoproteins, Insulin Resistance, and Systemic and Vascular Inflammation in Obesity and Diabetes

J. New, R. Donn, S. Hama, 2017, Front. Immunol..

A review of paradoxical HDL-C responses to fenofibrate, illustrated by a case report.

Yifen Liu, H. Soran, L. Sandle, 2014, Journal of clinical lipidology.

Familial hypercholesterolaemia commonly presents with Achilles tenosynovitis

P. Durrington, E. Benbow, V. Charlton-Menys, 2005, Annals of the rheumatic diseases.

Impairment of high-density lipoprotein resistance to lipid peroxidation and adipose tissue inflammation in obesity complicated by obstructive sleep apnea.

S. Hama, P. Pemberton, Yifen Liu, 2014, The Journal of clinical endocrinology and metabolism.

Homozygous familial hypercholesterolaemia: update on management

M. France, 2016, Paediatrics and international child health.

An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia

P. Durrington, D. Bhatnagar, M. Mackness, 2001, Heart.

HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom.

C. Shoulders, U. Ramaswami, G. Ferns, 2016, Atherosclerosis.

Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS).

G. Hitman, D. Demicco, H. Colhoun, 2009, Clinical chemistry.